Lucid Diagnostics (LUCD) Competitors

Lucid Diagnostics (NASDAQ:LUCD) and Talis Biomedical (NASDAQ:TLIS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings, media sentiment and community ranking.

Is LUCD or TLIS more profitable?

Lucid Diagnostics has a net margin of -1,576.60% compared to Talis Biomedical's net margin of -5,784.73%. Talis Biomedical's return on equity of -75.40% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-1,576.60%	-901.79%	-106.33%
Talis Biomedical	-5,784.73%	-75.40%	-56.16%

Do insiders & institutionals have more ownership in LUCD or TLIS?

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 46.0% of Talis Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the media refer more to LUCD or TLIS?

In the previous week, Lucid Diagnostics had 1 more articles in the media than Talis Biomedical. MarketBeat recorded 2 mentions for Lucid Diagnostics and 1 mentions for Talis Biomedical. Talis Biomedical's average media sentiment score of 1.88 beat Lucid Diagnostics' score of 1.19 indicating that Talis Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Lucid Diagnostics	Positive
Talis Biomedical	Very Positive

Which has more risk & volatility, LUCD or TLIS?

Lucid Diagnostics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Does the MarketBeat Community believe in LUCD or TLIS?

Lucid Diagnostics received 18 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 61.36% of users gave Lucid Diagnostics an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.

Company	Underperform	Outperform
Lucid Diagnostics	Outperform Votes 27 61.36%	Underperform Votes 17 38.64%
Talis Biomedical	Outperform Votes 9 37.50%	Underperform Votes 15 62.50%

Do analysts prefer LUCD or TLIS?

Lucid Diagnostics presently has a consensus target price of $2.75, indicating a potential upside of 208.82%. Talis Biomedical has a consensus target price of $5.00, indicating a potential downside of 45.65%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Talis Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Talis Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Which has better valuation & earnings, LUCD or TLIS?

Lucid Diagnostics has higher revenue and earnings than Talis Biomedical. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$2.43M	19.10	-$52.67M	-$1.27	-0.70
Talis Biomedical	$348K	48.17	-$62.01M	-$31.43	-0.29

Summary

Lucid Diagnostics beats Talis Biomedical on 11 of the 18 factors compared between the two stocks.